Three Breakthrough Advantages of Tirzepatide: The Science Behind Its Global Dominance
Market data reveals Tirzepatide captured 35% of the GLP-1 agonist market within 18 months of launch, while semaglutide growth slowed to 12%. This seismic shift stems from three revolutionary advantages: 1. Dual-Target Mechanism: Superior Metabolic Control Molecular Advantage Drug Target Pathway Activation Semaglutide GLP-1 monoagonist Single-pathway stimulation Tirzepatide GIP/GLP-1 dual agonist Synchronized glucose-insulin regulation Clinical […]
Three Breakthrough Advantages of Tirzepatide: The Science Behind Its Global Dominance Read More »